SB 687-FN (2020): relative to transparency in prescription drug pricing and establishing a New Hampshire prescription drug affordability board.

Cite this page

Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.

MLA
“SB 687-FN (2020): relative to transparency in prescription drug pricing and establishing a New Hampshire prescription drug affordability board.” Granite Record, https://graniterecord.org/bill/2020/sb687. Accessed 24 Oct. 2026.
APA
Granite Record. (n.d.). SB 687-FN (2020): relative to transparency in prescription drug pricing and establishing a New Hampshire prescription drug affordability board. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2020/sb687
Chicago
Granite Record. “SB 687-FN (2020): relative to transparency in prescription drug pricing and establishing a New Hampshire prescription drug affordability board.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2020/sb687.
BibTeX
@misc{bill-2020-sb687, title = {SB 687-FN (2020): relative to transparency in prescription drug pricing and establishing a New Hampshire prescription drug affordability board.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2020/sb687}, note = {Accessed 24 Oct. 2026} }

SB 687-FN (2020)

relative to transparency in prescription drug pricing and establishing a New Hampshire prescription drug affordability board.

  • Status: Died on the table
  • Term: 2019-2020
  • Senate committee: Commerce
  • Subject: Public and Mental Health

The Story

It was introduced on January 8, 2020 and referred to the Senate Commerce committee. The committee held a public hearing on January 21, 2020. The committee recommended that the Senate pass it with changes (amendment 2020-1062s). The committee's amendment (2020-1062s) was adopted on a voice vote on March 11, 2020, changing the text of the bill. On March 11, 2020 the Senate voted to pass it with changes on a voice vote and ordered it to a third reading.

Sponsors

Hearings and Sessions

  • January 21, 2020, 1:45 PM: hearing, Senate Commerce, SH 100

Votes

  • March 11, 2020, Senate: Ought to Pass with Amendment 2020-1062s — voice vote, passed

The Docket

  • January 8, 2020: Introduced 01/08/2020 and Referred to Commerce
  • January 21, 2020: Hearing: 01/21/2020, Room 100, SH, 01:45 pm
  • March 11, 2020: Committee Report: Ought to Pass with Amendment #2020-1062s , 03/11/2020
  • March 11, 2020: Committee Amendment #2020-1062s , AA, VV; 03/11/2020
  • March 11, 2020: Ought to Pass with Amendment 2020-1062s, MA, VV; OT3rdg; 03/11/2020
  • June 30, 2020: Introduced and Laid on Table MA VV 06/30/2020
  • September 23, 2020: Died on Table

Related Bills

  • HB 1280-FN (2020): relative to copayments for insulin, establishing a wholesale prescription drug importation program, establishing a New Hampshire prescription drug affordability board, establishing the prescription drug competitive marketplace, relative to the pricing of generic prescription drugs, relative to prior authorization for prescription drug coverage, and requiring insurance coverage for epinephrine auto-injectors.
  • HB 1280-FN (2020): relative to copayments for insulin, establishing a wholesale prescription drug importation program, establishing a New Hampshire prescription drug affordability board, establishing the prescription drug competitive marketplace, relative to the pricing of generic prescription drugs, relative to prior authorization for prescription drug coverage, and requiring insurance coverage for epinephrine auto-injectors.

From the General Court